Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of ALD518 for Reducing Oral Mucositis in Head and Neck Cancer Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Have recently diagnosed (\< than 6 months prior to screening visit date), pathologically confirmed, non-metastatic SCC of the oral cavity, oropharynx, hypopharynx or larynx that will be treated with CRT as first-line treatment; subjects with a history of surgical management (approximately 4-6 weeks before RT with sufficient time for post-surgical healing) are eligible~* Have a plan to receive a continuous course of conventional external beam irradiation delivered by intensity-modulated radiotherapy (IMRT) as single daily fractions of 2.0 to 2.2 Gy, with a cumulative radiation dose between 55 and 72 Gy.~* Have a plan to receive a standard cisplatin CT regimen administered tri-weekly (80 to 100 mg/m2, on Days 0, 21, and 42) or weekly (30 to 40 mg/m2) or a standard carboplatin regimen administered weekly (100 mg/m2)~* Have an Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1~* CRP \< 80 mg/L~* Have adequate hematopoietic, hepatic, and renal function at the screening visit~Exclusion Criteria:~* Tumor of the lips, sinuses, salivary glands, nasopharynx or unknown primary tumor~* Metastatic disease (M1) Stage IV C~* Any prior history of head and neck cancer~* Prior radiation to the head and neck~* Have had a major surgical procedure, other than for HNC, or significant traumatic injury within 4 weeks prior to the initiation of RT; or anticipation of need for a major surgical procedure during the clinical trial~* Active infectious disease, excluding oral candidiasis~* Have OM at the screening visit~* Have a history of hypersensitivity to monoclonal antibody

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Open Label ALD518 (Type: EXPERIMENTAL): None
- ALD518 Dose 1 (Type: EXPERIMENTAL): None
- ALD518 Dose 2 (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).